CorMedix Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, CorMedix is in Stage 3, the topping phase, now in week 2 (since Oct 14, 2026). It closed at $8.10, 36.4% below its 52-week high and above its 200-day average, which is falling.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. More about the company

$8.10

+3.45% today

$631M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is CRMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S2 17w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 18w → S1 5w → S4 6w → S1 3w → S2 12w → S3 9w → S2 17w → S3 5w → S2 8w → S3 7w → S2 12w → S3 8w → S2 2w → S3 5w → S4 5w → S1 2w → S4 16w → S1 13w → S4 9w → S3 1w current

Total tracked: 164 weeks across 21 stage runs.

CRMD among Biotechnology282nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…282	CRMDCorMedix Inc.	Stage 3 · wk 2	33	+5.3%

vs 52W High

-36.4%

$6.25 lo$12.73 hi

36.4% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

5.4%

200 DMA: $7.68 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.92x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+5.3%

+2.9%

+10.5%

YTD

-33.4%

-30.5%

Scan Membership

Breakout Watch

Latest: 2025-05-19

12 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.92x

2026-10-21S3

Wk 2 · Vol 0.72x

2026-10-20S3

Wk 1 · Vol 0.82x

2026-10-19S3

Wk 1 · Vol 1.26x

2026-10-16S3

Wk 1 · Vol 0.98x

2026-10-15S3

Wk 1 · Vol 1.28x

2026-10-14S34→3

Wk 1 · Vol 0.99x

2026-10-13S4

Wk 10 · Vol 1.26x

2026-10-12S4

Wk 9 · Vol 1.44x

2026-10-09S4

Wk 9 · Vol 1.08x

2026-10-08S4

Wk 9 · Vol 0.92x

2026-10-07S4

Wk 9 · Vol 0.74x

Moving averages & range

50 DMA

$7.86

200 DMA

$7.68

52W High

$12.73

52W Low

$6.25

5D Low

$7.26

Resistance levels (recent highs)

20d High

$8.10

60d High

$8.61

120d High

$8.96

250d High

$12.73

Next resistance

+6.3%

to 60d High

P/E (TTM)

4.0

Forward 23.1

Earnings Growth (YoY)

+6.7%

Revenue +156.5%

ROE

+54.9%

Profit margin +40.5%

Dividend Yield

0.00%

P/B 1.4

CorMedix: quick answers

What stage is CorMedix in?

As of Oct 22, 2026, CorMedix (CRMD) is in Stage 3, the topping phase. It entered Stage 3 on Oct 14, 2026 and is in week 2. What the four stages mean

Is CorMedix in an uptrend?

Its uptrend has stalled. CorMedix is in Stage 3, the topping phase that follows an advance. It trades 5.4% above its 200-day average, which is falling.

How far is CorMedix from its 52-week high?

CorMedix closed at $8.10 on Oct 22, 2026, 36.4% below its 52-week high of $12.73. Its 52-week low is $6.25.

How has CorMedix performed over the past year?

As of Oct 22, 2026, CorMedix is down 30.5% over the past year and down 33.4% so far in 2026.

Which sector and industry is CorMedix in?

CorMedix is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.